Tag: AMT-060

August 3, 2017

uniQure Gets Back Gene Therapy After Chiesi Ends Partnership

uniQure will regain the rights for their hemophilia B gene therapy as the Chiesi Group backs out from working partnership...
July 31, 2017

uniQure Reacquires Rights for Gene Therapy Candidate

uniQure N.V. entered an agreement with Chiesi Group to reacquire the rights to co-develop and commercialize its hemophilia B gene...
July 11, 2017

uniQure Presents New Clinical Data in Hemophilia B Patients

uniQure N.V. presented new clinical data from the ongoing Phase I-II trial of AMT-060.
April 25, 2017

uniQure Receives PRIME Designation in Europe

uniQure announced their gene therapy AMT-060, received PRIME designation from the European Medicines Agency.